Project Grant R01HL177974
Award Date
1/10/25
Completion Date
11/30/28
Dollars Obligated
$674K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,545,248 to support a 5-year observational study investigating the longitudinal association between post-infarct lipomatous metaplasia (LM) and malignant arrhythmia in patients with prior myocardial infarction (MI). The study aims to define the relationship between reperfusion injury, LM incidence and progression, and the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $634,183 to Loyola University of Chicago's Health Sciences Campus to investigate the molecular mechanisms of cardiac ryanodine receptor (RyR) dysfunction during oxidative stress and myocardial infarction. The research aims to define how oxidative stress-induced intersubunit cross-linking of the RyR calcium channel alters its...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $126,442 to the Regents of the University of Minnesota to conduct research on the effects of hyperglycemia and recovery on aortic growth and remodeling. The overarching objective is to determine how chronic hyperglycemia impacts aortic biomechanics and mechanobiology, and whether restoration of normoglycemia can reverse...
This $2,352,138 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to model cell-specific signaling of the Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) in acute myocardial infarction (AMI). The research aims to expand and validate signaling networks that predict how early LRP1 signaling in cardiomyocytes enhances cell survival after ischemia-reperfusion, as well as how late...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $116,250.00 to the Regents of the University of Minnesota to conduct research on identifying the underlying causes of cardiomyopathy. The research aims to evaluate the use of cardiac magnetic resonance imaging to reclassify the causes of cardiomyopathy, which could lead to more accurate diagnosis and appropriate...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,706,807.00 to the Regents of the University of Michigan to support research on small-molecule effectors targeting cardiac ion pumps. The overarching goals are to determine the structural mechanisms for small-molecule activation of the cardiac calcium pump (SERCA) and discover new classes of non-cardiotoxic inhibitors of the cardiac sodium pump (NKA)....
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), totals $618,126 and supports research into the mechanisms by which the cytokine interleukin-6 (IL-6) contributes to ventricular tachyarrhythmias and sudden cardiac death, particularly in the context of obesity-related inflammation. The research aims to elucidate how IL-6 trans-signaling triggers...
The federal Project Grant award "USING DEFECTIVE LIPOYLATION AS A WINDOW INTO CARDIAC FUEL CONSUMPTION AND FAILURE" is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $154,568 award, spanning Dec 2024 to Aug 2027, supports research to characterize the cardiac metabolic and functional consequences of lipoyl deficiency at the University of Texas Southwestern Medical Center. The central hypothesis is...
This $704,071 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to elucidate the molecular mechanisms by which mutations in the LMNA gene promote cardiac conduction disorders. The project aims to establish the pathological function of LMNA in the development of cardiac conduction disorders, which can lead to conditions like sick sinus syndrome and atrioventricular block. A key...